报价延迟最少15分钟:2025/07/21 06:38 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.8092
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.39/-0.98
|
|
企业价值
38.19M
|
| 资产负债 |
|
每股账面净值
1.41
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
5.72M
|
|
每股收益
0.02
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 06:38 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325,which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD. |
